Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Reduced ICU Length of Stay with FlowTriever Mechanical Thrombectomy in Acute PE: A Retrospective Cohort Study
Session:
Sessão de Posters 33 - Cardiopatia congénita e hipertensão pulmonar: da evidência à ação
Speaker:
Mariana Caetano Coelho
Congress:
CPC 2026
Topic:
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Theme:
20. Congenital Heart Disease and Pediatric Cardiology
Subtheme:
20.2 Congenital Heart Disease – Epidemiology, Prognosis, Outcome
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Mariana Caetano Coelho; Julien Lopes; Daniela Pinheiro; Barbara Lacerda Teixeira; Andre Grazina; João Reis; Pedro Costa; Ana Galrinho; Melanie Ferreira; Pedro Coelho; Rui Cruz Ferreira; Luis Almeida Morais
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif">Bacground: Pulmonary embolism (PE) is a life-threatening condition that often requires rapid reperfusion to prevent right-ventricular failure and prolonged intensive care stay. Modern percutaneous strategies such as catheter-directed thrombolysis (CDT) improve pulmonary pressures but are limited by bleeding risk and the frequent need for ICU monitoring to manage thrombolytic infusion (1). Mechanical thrombectomy has emerged as an alternative that provides faster hemodynamic improvement without thrombolytics. </span></span><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif">Among these devices, the FlowTriever system has shown significant potential to reduce ICU utilization. The FLARE trial demonstrated that 41% of treated patients required no ICU stay, and the mean ICU duration was only 1.5 days (2). Real-world data from the FLASH registry similarly reported rapid clinical stabilization and low rates of ICU admission (3). Comparative observational studies also suggest shorter ICU stays with FlowTriever versus standard catheter-based therapies (4).</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif">Aim: The aim of this study is to evaluate whether the FlowTriever mechanical thrombectomy system reduces ICU length of stay compared with other percutaneous treatment strategies for acute pulmonary embolism.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif">Methos/Results: We conducted a retrospective analysis of all patients treated for acute pulmonary embolism at our center between 2020 and 2025. A total of 159 patients were included, with a median age of 62 years (IQR ±16) and 48% women. Based on hemodynamic presentation, 9% were classified as high-risk PE, while the remainder met criteria for intermediate-high–risk PE. Patients were grouped according to the reperfusion strategy used: systemic fibrinolysis (n=99), combined fibrinolysis plus mechanical therapy (n=12), Penumbra thrombectomy (n=6), FlowTriever thrombectomy (n=37), and EKOS catheter-directed thrombolysis (n=5). The primary endpoint was ICU length of stay, measured in days and compared across treatment modalities.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif">Baseline characteristics were similar across treatment groups, with no statistically significant differences in age (p=0.95), sex distribution (p=0.25), high-risk presentation (p=0.301), syncope (p=0.766), or dyspnea (p=0.253). A higher proportion of cardiac arrest events was observed in the EKOS group, although this difference did not reach statistical significance (p=0.053).</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif">In this cohort with acute pulmonary embolism, ICU length of stay varied significantly across reperfusion strategies (ANOVA F = 5.48; p < 0.001). FlowTriever was associated with the shortest ICU stay (2.78 days), followed by EKOS (3.1 days), fibrinolysis (3.42 days), combined therapy (3.7 days), and Penumbra (9 days).</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif">Conclusion: FlowTriever demonstrated a consistent trend toward shorter ICU stays compared with other percutaneous techniques, suggesting a potential clinical advantage as well as economic and logistical benefits.</span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site